Investigators assessed long-term PFS and safety results for acalabrutinib, bendamustine, and rituximab in the phase 3 ECHO trial.
Please provide your email address to receive an email when new articles are posted on . Accounting for the presence of multiple, concurrent central lines when calculating central line-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback